Today: 22 January 2026
Subscribe
Browse Category

Pharmaceuticals News 14 January 2026 - 15 January 2026

Eli Lilly stock dips after hours as FDA seeks label change for Zepbound, traders eye obesity pill push

Eli Lilly stock dips after hours as FDA seeks label change for Zepbound, traders eye obesity pill push

NEW YORK, Jan 14, 2026, 6:33 PM EST — After-hours Eli Lilly shares slipped in after-hours trading Wednesday, as investors digested a U.S. regulatory update on weight-loss drug labels alongside new marketing chatter about the company’s upcoming obesity treatment. The FDA’s move to remove suicide warnings from GLP-1 weight-loss drugs comes at a tricky time for the sector. Demand is…
15 January 2026
···
Johnson & Johnson stock rises after Tecvayli trial win as JNJ eyes earnings

Johnson & Johnson stock rises after Tecvayli trial win as JNJ eyes earnings

New York, Jan 14, 2026, 18:15 EST — After-hours Johnson & Johnson shares climbed 2.3% to $218.55 in after-hours trading Wednesday following upbeat topline data from a late-stage multiple myeloma study for Tecvayli. Investors are zeroing in on Johnson & Johnson’s drug pipeline for the next growth phase as the company gears up for its quarterly report next week. Oncology…
15 January 2026
····
Pfizer (PFE) stock rises as CEO calls obesity push a “Viagra”-scale bet, with earnings next in focus

Pfizer (PFE) stock rises as CEO calls obesity push a “Viagra”-scale bet, with earnings next in focus

NEW YORK, Jan 14, 2026, 15:10 EST — Regular session Pfizer Inc shares climbed about 2% to $25.65 on Wednesday following CEO Albert Bourla’s remarks on the company’s push into the rapidly expanding cash-pay obesity drug market. “We are all in on obesity,” Bourla told reporters at the J.P. Morgan Healthcare Conference. Pfizer plans to launch 10 Phase 3 trials…
14 January 2026
···
Viridian Therapeutics stock jumps to a 52-week high as VRDN traders zero in on June FDA deadline

Viridian Therapeutics stock jumps to a 52-week high as VRDN traders zero in on June FDA deadline

New York, January 14, 2026, 14:14 EST — Regular session Viridian Therapeutics shares climbed 6.4% to $34.03 in early afternoon trading on Wednesday, after hitting an intraday high of $34.25, a new 52-week peak. The gain bucked a softer market. The Invesco QQQ Trust, a proxy for the Nasdaq 100, was down about 1.5%, while the SPDR S&P 500 ETF…
14 January 2026
····
Nuvalent stock jumps as FDA review clock sharpens focus on 2026 launch plans

Nuvalent stock jumps as FDA review clock sharpens focus on 2026 launch plans

New York, Jan 14, 2026, 14:09 EST — Regular session Nuvalent’s stock climbed roughly 6% Wednesday afternoon, building on earlier gains as the biotech detailed crucial 2026 goals for its lead lung-cancer project and highlighted a sizable cash pile expected at year-end. This matters since Nuvalent remains a clinical-stage company. Investors want a clearer timeline for its first possible U.S.…
14 January 2026
···
Structure Therapeutics stock jumps as Novo deal talk lifts obesity-drug names

Structure Therapeutics stock jumps as Novo deal talk lifts obesity-drug names

New York, January 14, 2026, 13:46 EST — Regular session Shares of Structure Therapeutics (GPCR) jumped roughly 7.5% Wednesday, as traders returned to small-cap obesity drugmakers. The stock climbed to $83.76, trading over 1 million shares. This shift is crucial as investors wager the weight-loss craze will move from weekly injections to pills, reshaping the buyout landscape. A Novo Nordisk…
14 January 2026
···
Terns Pharmaceuticals stock jumps 10% as JPM conference puts TERN-701 back on the map

Terns Pharmaceuticals stock jumps 10% as JPM conference puts TERN-701 back on the map

New York, Jan 14, 2026, 12:57 EST — Regular session Terns Pharmaceuticals (TERN.O) shares jumped over 10% Wednesday, fueled by the company’s newest conference update on its lead cancer drug. By midday, the stock had risen 10.4% to $38.03, after trading in a range from $34.05 to $38.35. The shift coincides with biotech investors flocking to the annual J.P. Morgan…
14 January 2026
····
Pfizer stock rises as CEO likens obesity-drug boom to Viagra ahead of Feb. 3 earnings

Pfizer stock rises as CEO likens obesity-drug boom to Viagra ahead of Feb. 3 earnings

NEW YORK, Jan 14, 2026, 11:47 EST — Regular session Pfizer Inc shares climbed Wednesday following CEO Albert Bourla’s renewed commitment to fast-track obesity drugs, a crucial focus as the company navigates patent losses and adjusts post-COVID. This move is crucial as investors demand evidence that Pfizer can develop fresh growth drivers ahead of a tough run of patent expirations.…
14 January 2026
··
Eli Lilly stock slips as FDA drops suicide warning for Zepbound; traders eye orforglipron, earnings next

Eli Lilly stock slips as FDA drops suicide warning for Zepbound; traders eye orforglipron, earnings next

New York, Jan 14, 2026, 11:40 AM EST — Regular session Eli Lilly and Company shares slipped Wednesday following a move by U.S. regulators to remove suicide-related warnings from several popular obesity drugs, including Lilly’s Zepbound. The stock was down roughly 0.4%, trading near $1,072.89 by late morning. (U.S. Food and Drug Administration) The label change is significant because it…
14 January 2026
····
Johnson & Johnson stock rises on Auris court win as talc fight and Jan. 21 earnings loom

Johnson & Johnson stock rises on Auris court win as talc fight and Jan. 21 earnings loom

New York, Jan 14, 2026, 11:23 EST — Regular session Johnson & Johnson shares climbed 1.9% to $217.80 by late morning Wednesday, defying the SPDR S&P 500 ETF, which dipped roughly 1%. Healthcare outperformed the broader market. The Health Care Select Sector SPDR ETF edged up slightly, with Merck, Pfizer, and AbbVie each adding about 0.6%, 0.6%, and 0.5%, respectively.…
14 January 2026
····
Gelteq Limited stock jumps in premarket after CBD gel study; what’s next for GELS

Gelteq Limited stock jumps in premarket after CBD gel study; what’s next for GELS

NEW YORK, Jan 14, 2026, 08:42 AM EST — Premarket Gelteq Limited shares surged roughly 48% to $1.23 in premarket action Wednesday, following a 6.4% gain at Tuesday’s close. (StockAnalysis) The Nasdaq-listed biotech revealed that a recent preclinical study demonstrated its ingestible gel delivery platform boosts cannabidiol (CBD) absorption over an FDA-approved oil-based option. Gelteq also indicated these findings might…
14 January 2026
···
NRXP stock slips premarket as NRx says FDA fast-tracked ketamine bid with 70,000-patient dataset

NRXP stock slips premarket as NRx says FDA fast-tracked ketamine bid with 70,000-patient dataset

New York, Jan 14, 2026, 08:52 EST — Premarket NRx Pharmaceuticals shares dropped 4.3% to $2.13 in premarket on Wednesday. The FDA granted Fast Track status to NRX-100, the company’s preservative-free ketamine treatment targeting suicidal ideation. NRx plans to submit real-world data from over 70,000 patients to back an accelerated approval application. CEO Jonathan Javitt noted, “An American commits suicide…
14 January 2026
····
1 … 3 4 5 6 7 … 45

Stock Market Today

  • Four Seasons Education (NYSE:FEDU) Shares Tumble 30% Amid Mixed Growth Signals
    January 22, 2026, 6:48 AM EST. Shares of Four Seasons Education (Cayman) Inc. (NYSE:FEDU) have plunged 30% in the past month, continuing a difficult 27% decline over the last year. Despite a seemingly attractive price-to-earnings (P/E) ratio of 13.5x, below the U.S. market average of roughly 20x, the company's uneven earnings growth raises concerns. After a striking 323% earnings per share increase last year, the firm showed no growth across the past three years, suggesting inconsistent performance. This lag behind the broader market's projected 16% expansion likely explains the low P/E and wary investor sentiment. The sharp stock drop reflects caution about the company's future growth prospects, signaling that its current valuation more so captures investor apprehension than undervaluation.
Go toTop